Multiple Myeloma

Preliminary phase II data on proteasome inhibitor MLN341 promising

Published in Cancer Weekly, July 23rd, 2002

Millennium Pharmaceuticals, Inc., (MLNM) announced updated preliminary findings of a phase II clinical trial of its investigational drug MLN341 (formerly known as LDP-341 and PS-341) in patients with multiple myeloma, the second most common hematologic cancer, whose disease has relapsed and not responded following multiple prior treatments.

The study results showed that MLN341 stabilized or reduced myeloma (M) protein, a primary marker of cancer burden, in the majority of study participants, with manageable and predictable side effects. In addition, the majority of patients did not experience disease progression during the 24 week study. The results were announced at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-07-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry